CyclASol for the Treatment of Signs and Symptoms of Dry Eye Disease in Subjects Who Completed CYS-004
A Phase 3, Multi-center, Open-label, Single-arm Clinical Trial to Assess the Long-term Safety and Tolerability of Topical CyclASol® for the Treatment of Dry Eye Disease in Subjects Who Completed the Clinical Trial CYS-004
Sponsor: Novaliq GmbH
This PHASE3 trial investigates Dry Eye Disease (DED) and is currently completed. Novaliq GmbH leads this study, which shows 10 recorded versions since 2021 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Nov 2023 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2023 — Nov 2023 [monthly]
Completed PHASE3
-
Sep 2022 — Jan 2023 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
▶ Show 5 earlier versions
-
Oct 2021 — Sep 2022 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Apr 2021 — Oct 2021 [monthly]
Recruiting PHASE3
-
Feb 2021 — Apr 2021 [monthly]
Recruiting PHASE3
Status: Not Yet Recruiting → Recruiting
-
Jan 2021 — Feb 2021 [monthly]
Not Yet Recruiting PHASE3
-
Sep 2020 — Jan 2021 [monthly]
Not Yet Recruiting PHASE3
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Novaliq GmbH
For direct contact, visit the study record on ClinicalTrials.gov .